Endoscopy Device Sales Will Reach $42 Billion In 2020, According To New Visiongain Data.

04 September 2018
Pharma

A new report by visiongain forecasts that sales of endoscopy devices worldwide will reach $42bn in 2020. Revenue growth will continue through to 2026, with rising demand for minimally invasive medical procedures.

That sales prediction and others appear in Endoscopy Systems Industry and Market: Forecasts and Discussions 2016-2026 – Laparoscopy, Urology, Gastrointestinal Uses, Arthroscopy, ENT Endoscopy and Gynaecology, Assessing Technologies Including Enteroscopy, Colonoscopy, Capsule Endoscopy, ERCP, Rhinoscopy, Laryngoscopy, Bronchoscopy, Cystoscopy, Ureteroscopy, Prenatal Applications and Sales in the US, Japan, Germany, France, UK, Italy, Spain, China and India.

The updated study, published in July 2016, analyses events, prospects and opportunities shaping the development, production and marketing of endoscopic devices for medicine. Visiongain’s investigation shows multilevel revenue forecasting and qualitative assessments for those systems in diagnostics and surgery. That work also explores activities of companies providing endoscopy devices, assessing their potentials. The healthcare endoscopy market holds many technological and commercial opportunities from 2016, including rising sales in developed and developing countries.

Market growth is driven by the rising incidence and prevalence of chronic diseases worldwide, which drive demand for new, improved diagnostic and therapeutic endoscopic procedures in developed and emerging national markets.

Aanchal Verma, a pharmaceutical industry analyst in visiongain, said: “A key factor in the growth of the medical devices market is endoscopy, which has progressed rapidly in recent years owing primarily to an increased patient demand in minimally invasive procedures for treatment and diagnosis purposes. Technological advances propelled the field of endoscopy, with new and innovative devices offering enhanced image quality and access to regions of the body previously thought as difficult to access.

“The increasingly improving healthcare systems and economic prosperity in the emerging markets will be a main driver of growth within the endoscopy devices market. Furthermore, the rise in incidences of chronic diseases, improvements in technology, awareness of early screening and the demand for minimally invasive procedures will fuel strong demand for endoscopy devices globally.”

Visiongain’s new study gives revenue predictions to 2026 for seven medical endoscopy submarkets at world level:

• Laparoscopy
• Urology
• Gastrointestinal uses
• Arthroscopy
• Ear, nose and throat (ENT) endoscopy
• Gynaecological uses
• Other applications.

That report shows revenue prospects in developed and developing markets, with revenue forecasts to 2026 for nine countries:

• US
• Japan
• Germany, France, UK, Italy and Spain
• China and India.

From 2016, large medical devices companies and other specialists can prosper in that market. Companies discussed include these organisations:

• Karl Storz
• Smith and Nephew
• Olympus
• Stryker
• Richard Wolf
• Given Imaging
• Fujifilm.

Endoscopy Systems Industry and Market: Forecasts and Discussions 2016-2026 adds to visiongain’s reports on industries and markets in healthcare. That portfolio covers pharmaceuticals, medical devices, diagnostics and outsourced services.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever